Association of Combined Estrogen-Progestogen and Progestogen-Only Contraceptives with the Development of Cancer

被引:7
作者
Williams, William V. [1 ,2 ]
Mitchell, Louise A. [3 ]
Carlson, S. Kathleen [4 ]
Raviele, Kathleen M. [5 ]
机构
[1] BriaCell Therapeut Corp, W Vancouver, BC, Canada
[2] Univ Penn, Med, Philadelphia, PA 19104 USA
[3] Catholic Med Assoc, Bala Cynwyd, PA USA
[4] Univ Virginia, Charlottesville, VA USA
[5] Dekalb Med, Decatur, GA USA
关键词
Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Contraception; Contraceptive; Endometrial cancer; Estrogen; Ovarian cancer; Progestogen;
D O I
10.1177/0024363918811637
中图分类号
R-052 [医学伦理学];
学科分类号
0101 ; 120402 ;
摘要
Combined estrogen-progestogen contraceptives (oral contraceptives or OCs) and progestogen-only contraceptives (POCs) are synthetic steroids that bind to steroid hormone receptors, which are widespread throughout the body. They have a profound effect on cellular physiology. Combined OCs have been classified by the International Agency for Research on Cancer (IARC) as Group 1 carcinogens, but their findings have not been updated recently. In order to update the information and better understand the impact that OCs and POCs have on the risk of development of cancers, a comprehensive literature search was undertaken, focusing on more recently published papers. In agreement with the IARC, the recent literature confirms an increased risk of breast cancer and cervical cancer with the use of OCs. The recent literature also confirms the IARC conclusion that OCs decrease the risk of ovarian and endometrial cancers. However, there is little support from recent studies for the IARC conclusion that OCs decrease the risk of colorectal cancer or increase the risk of liver cancer. For liver cancer, this may be due to the recent studies having been performed in areas where hepatitis is endemic. In one large observational study, POCs also appear to increase the overall risk of developing cancer. OCs and POCs appear to increase the overall risk of cancer when carefully performed studies with the least intrinsic bias are considered. OCs have been classified as cancer-causing agents, especially leading to increases in breast cancer and cervical cancer. A review of the recent scientific literature was performed to see whether this still appears to be the case. The recent literature supports the cancer-causing role of OCs especially for breast cancer and cervical cancer. Studies also indicate that progesterone-only contraceptives (such as implants and vaginal rings) also can cause cancer. This is especially true for breast cancer and cervical cancer.
引用
收藏
页码:412 / 452
页数:41
相关论文
共 165 条
  • [1] Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies
    Allen, N.
    Peto, R.
    Beral, V.
    Kan, S. W.
    Reeves, G.
    Sweetland, S.
    Stevens, R.
    Yang, T. O.
    [J]. LANCET ONCOLOGY, 2015, 16 (09) : 1061 - 1070
  • [2] Altman DG, 1991, PRACTICAL STAT MED R
  • [3] Hormonal Therapy and Risk of Breast Cancer in Mexican Women
    Amadou, Amina
    Fabre, Alban
    Torres-Mejia, Gabriela
    Ortega-Olvera, Carolina
    Angeles-Lierenas, Angelica
    McKenzie, Fiona
    Biessy, Carine
    Hainaut, Pierre
    Romieu, Isabelle
    [J]. PLOS ONE, 2013, 8 (11):
  • [4] Oral Contraceptives Use and Liver Cancer Risk A Dose-Response Meta-Analysis of Observational Studies
    An, Ning
    [J]. MEDICINE, 2015, 94 (43)
  • [5] Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study
    Antoniou, Antonis C.
    Rookus, Matti
    Andrieu, Nadine
    Brohet, Richard
    Chang-Claude, Jenny
    Peock, Susan
    Cook, Margaret
    Evans, D. Gareth
    Eeles, Rosalind
    Nogues, Catherine
    Faivre, Laurence
    Gesta, Paul
    van Leeuwen, Flora E.
    Ausems, Margreet G. E. M.
    Sorio, Ana
    Caldes, Trinidad
    Simard, Jacques
    Lubinski, Jan
    Gerdes, Anne-Marie
    Olah, Edith
    Fuerhauser, Christine
    Olsson, Hakan
    Arver, Brita
    Radice, Paolo
    Easton, Douglas F.
    Goldgarl, David E.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (02) : 601 - 610
  • [6] Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5
  • [7] Incidence rate of ovarian cancer in Iran in comparison with developed countries
    Arab, M.
    Khayamzadeh, M.
    Tehranian, A.
    Tabatabaeefar, M.
    Hosseini, M.
    Anbiaee, R.
    Golfam, F.
    Akbari, M. E.
    [J]. INDIAN JOURNAL OF CANCER, 2010, 47 (03) : 322 - 327
  • [8] Reproductive Factors, Hormone Use, and Risk for Lung Cancer in Postmenopausal Women, the Nurses' Health Study
    Baik, Christina S.
    Strauss, Gary M.
    Speizer, Frank E.
    Feskanich, Diane
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (10) : 2525 - 2533
  • [9] Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age
    Beaber, Elisabeth F.
    Buist, Diana S. M.
    Barlow, William E.
    Malone, Kathleen E.
    Reed, Susan D.
    Li, Christopher I.
    [J]. CANCER RESEARCH, 2014, 74 (15) : 4078 - 4089
  • [10] Oral Contraceptives and Breast Cancer Risk Overall and by Molecular Subtype Among Young Women
    Beaber, Elisabeth F.
    Malone, Kathleen E.
    Tang, Mei-Tzu Chen
    Barlow, William E.
    Porter, Peggy L.
    Daling, Janet R.
    Li, Christopher I.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (05) : 755 - 764